Innovative and Patented Pre-Filled Devices

Who We Are

We are a medical device start-up with 3 patents.
 

Why Are We Unique

• QuickInject: uses BFS manufacturing to create, fill, sterilize, and seal the device with a safety cap within the machine. Adding a specific needle size is an option.
  
  
• QuickInject-Safety Shield: this device can be manufactured with blow molding and/or blow fill seal manufacturing processes.

The Market

Syringe History:  the syringe concept is 100 years old.  PFS, prefilled syringes 1st came into vogue in Europe ~ 2008.  PFS syringes are in common use worldwide.  BFS has been used to make sterile containers. The cost advantages in making containers with BFS  is less by ~ a factor of 10; if not even less costly. 1-The syringe is made in 3 parts and > rubber stopper requires silicon to move within the barrel. 2-The completed syringe is then sent to a filling system to fill it, sterilize it, and label it. (etc.)

Market outlook: for PFS and our products the market is positive.  Startup entities will expand the market > Please see additional readings for 3rd party positive comments on the product’s benefits page. Small startup entities will actively advance this market with unique products

The Ask: to develop a partnership to license our single use patented prefilled devices using BFS system technology.

Adar’s Unique Devices: 

• We have a patented device that is created entirely within the BFS system, an single step manufacturing process makes our device.
• Product runs can be long, 1 million devices, or short: to make devices for FDA phase 1,2, or 3 Investigational studies by a manufacturer.
• Outstanding Engineering support: PADT in Tempe, Az and Weiler Engineering in Illinois have worked with us from 2009, 2010; respectively.
• For high cost biologicals we expect less waste vs other injection systems.
• We have CAD drawings for both QI and QISS.
• No suspended particulates to contaminate the molecule in our container.

Forward looking comments:

• A PFS manufacturer is our partner. The devices are being made.
• There are real life cases for the case below, with Billions of $’s at risk when the patent on their molecule expires. Any search will validate the income stream on top injectables sold yearly.
• Hypothetical case: Firm XYZ molecule will expire in 2-5 years. Our PFS licensing partner meets with XYZ with a plan: contract with us > to switch all PFS containing their Billion dollar/year molecule to Adar’s patented devices. Let’s assume it takes 6-12 months before the supply system only contains Adar’s devices.
• XYZ’s patent expires. How long before the supply chain empties of Adar’s devices?
  • 6 months saves ½ of a Billion
  • 4 months saves 1/3
  • 3 months saves ¼
• This analysis is only for 1 molecule

Disclaimer:  Whenever a new discovery enters a established market there is always a period of skepticism, market turmoil, and validation. Our focus has been both qualitative, along with financial assumptions to suggest the potential financial benefit.

Your Risk: to absorb the startup costs to develop the molds, create the integrated system software, then make the actual QI and QISS devices. Ask one of your smart MBA or financial analysists to do the quantitative math analysis.